Alexis Ogdie1, Neilia Kay McGill2, Daniel B Shin3, Junko Takeshita4, Thorvardur Jon Love5,6, Megan H Noe3, Zelma C Chiesa Fuxench3, Hyon K Choi7, Nehal N Mehta8, Joel M Gelfand3,9. 1. Division of Rheumatology, Department of Medicine, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, White Building, Room 5024, 3400 Spruce St, Philadelphia, PA, USA. 2. Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 3. Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, South Tower, 7th Floor, 3400 Civic Center Blvd, Philadelphia, PA, USA. 4. Department of Dermatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 5. Division of Rheumatology/Department of Medicine, Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 6. Department of Science, Landspitali University Hospital, Reykjavik, Iceland. 7. Division of Rheumatology and Allergy/Immunology, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 165, Boston, MA, USA. 8. Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, 10 Center Drive, Bethesda, MD, USA. 9. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, 8th Floor, Blockley Hall, 423 Guardian Drive, Philadelphia, PA, USA.
Abstract
Aims: To determine the risk of venous thromboembolism (VTE) defined as the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE) among patients with psoriatic arthritis (PsA), psoriasis and rheumatoid arthritis (RA) compared with population controls. Methods and results: A cohort study was conducted in a primary care medical record database in the UK with data from 1994-2014 among patients with PsA, RA, or psoriasis. Cox proportional hazards models were used to calculate the relative hazards for DVT, PE, and VTE. An interaction with disease modifying anti-rheumatic drugs (DMARD) was hypothesized a priori and was significant. Patients with PsA (n = 12 084), RA (n = 51 762), psoriasis (n = 194 288) and controls (n = 1 225 571) matched on general practice and start date were identified. Patients with RA (with and without a DMARD prescription) and patients with mild psoriasis had significantly elevated risks of VTE (HR 1.35, 1.29, and 1.07, respectively) after adjusting for traditional risk factors. Severe psoriasis and PsA prescribed a DMARD had an elevated but not statistically significant risk for VTE. Findings were similar for DVT. The age-and-sex-adjusted risk of PE was elevated in RA, severe psoriasis and PsA patients prescribed a DMARD. Conclusion: While systemic inflammation is a risk factor for VTE, the risk of VTE compared with controls is different among patients with three different inflammatory disorders: RA, PsA, and psoriasis.
Aims: To determine the risk of venous thromboembolism (VTE) defined as the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE) among patients with psoriatic arthritis (PsA), psoriasis and rheumatoid arthritis (RA) compared with population controls. Methods and results: A cohort study was conducted in a primary care medical record database in the UK with data from 1994-2014 among patients with PsA, RA, or psoriasis. Cox proportional hazards models were used to calculate the relative hazards for DVT, PE, and VTE. An interaction with disease modifying anti-rheumatic drugs (DMARD) was hypothesized a priori and was significant. Patients with PsA (n = 12 084), RA (n = 51 762), psoriasis (n = 194 288) and controls (n = 1 225 571) matched on general practice and start date were identified. Patients with RA (with and without a DMARD prescription) and patients with mild psoriasis had significantly elevated risks of VTE (HR 1.35, 1.29, and 1.07, respectively) after adjusting for traditional risk factors. Severe psoriasis and PsA prescribed a DMARD had an elevated but not statistically significant risk for VTE. Findings were similar for DVT. The age-and-sex-adjusted risk of PE was elevated in RA, severe psoriasis and PsA patients prescribed a DMARD. Conclusion: While systemic inflammation is a risk factor for VTE, the risk of VTE compared with controls is different among patients with three different inflammatory disorders: RA, PsA, and psoriasis.
Authors: Kimberly P Liang; Kelly V Liang; Eric L Matteson; Robyn L McClelland; Teresa J H Christianson; Carl Turesson Journal: Arthritis Rheum Date: 2006-02
Authors: Marie E Holmqvist; Martin Neovius; Jonas Eriksson; Ängla Mantel; Solveig Wållberg-Jonsson; Lennart T H Jacobsson; Johan Askling Journal: JAMA Date: 2012-10-03 Impact factor: 56.272
Authors: Danka J F Stuijver; Christof J Majoor; Bregje van Zaane; Patrick C Souverein; Anthonius de Boer; Olaf M Dekkers; Harry R Büller; Victor E A Gerdes Journal: Chest Date: 2013-05 Impact factor: 9.410
Authors: Lingyi Li; Na Lu; Ana Michelle Avina-Galindo; Yufei Zheng; Diane Lacaille; John M Esdaile; Hyon K Choi; J Antonio Aviña-Zubieta Journal: Rheumatology (Oxford) Date: 2021-01-05 Impact factor: 7.580
Authors: Alexis Ogdie; Sungat K Grewal; Megan H Noe; Daniel B Shin; Junko Takeshita; Zelma C Chiesa Fuxench; Rotonya M Carr; Joel M Gelfand Journal: J Invest Dermatol Date: 2017-11-02 Impact factor: 8.551
Authors: Kristin J Meyers; Jonathan I Silverberg; Maria Jose Rueda; Robert Goodloe; Evangeline J Pierce; Walter Deberdt; Dennis R Brinker Journal: Dermatol Ther (Heidelb) Date: 2021-04-30
Authors: Tom Hillary; Jolien Clijmans; Séverine Vermeire; Jo Lambert; Marjan Garmyn; Maya Imbrechts; Thomas Vanassche Journal: Ann Med Date: 2021-12 Impact factor: 4.709